文献速递瓣膜病与结构性心脏病

经导管缘对缘修复治疗三尖瓣反流:TRILUMINATE 研究一年结果

Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

TRILUMINATE 研究是一项国际、前瞻性、单臂、多中心研究,纳入 85 例中度及以上三尖瓣反流患者,评估 TriClip 经导管三尖瓣修复系统的安全性与性能。1 年时 71% 患者三尖瓣反流降至中度及以下(基线为 8%,p < 0.0001),NYHA I/II 级比例从 31% 升至 83%,6 分钟步行距离和 KCCQ 评分均显著改善,主要不良事件率与全因死亡率均为 7.1%。

要点

  • TriClip 经导管三尖瓣修复在中度及以上三尖瓣反流患者中安全有效
  • 1 年时 71% 患者三尖瓣反流降至中度及以下,修复效果持久
  • 临床获益显著:NYHA 分级、6 分钟步行距离和 KCCQ 评分均改善

核心结论

  • TriClip 经导管三尖瓣修复在中度及以上三尖瓣反流患者中安全有效,1 年时修复效果持久并伴随持续显著临床获益且死亡率低。

研究设计与样本

  • TRILUMINATE 研究为国际、前瞻性、单臂、多中心研究,纳入 85 例中度及以上三尖瓣反流患者,评估 TriClip 三尖瓣修复系统的安全性与性能,超声心动图由核心实验室评估。

主要发现

  • 1 年时 71% 受试者三尖瓣反流降至中度及以下,基线为 8%(p < 0.0001)。
  • NYHA 功能分级 I/II 级比例从 31% 升至 83%(p < 0.0001)。
  • 6 分钟步行距离从 272.3 ± 15.6 米增至 303.2 ± 15.6 米(p = 0.0023)。
  • KCCQ 评分改善 20 ± 2.61 分(p < 0.0001),并观察到右心室大小和功能的显著逆转重构。
  • 1 年时总体主要不良事件率和全因死亡率均为 7.1%。

临床怎么用

  • 对于中度及以上三尖瓣反流且外科高危的患者,TriClip 经导管三尖瓣修复可作为安全有效的治疗选择。

局限性

  • 研究为单臂设计,样本量 85 例,缺乏对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Tricuspid regurgitation (TR) is a frequent disease with a progressive increase in mortality as disease severity increases. Transcatheter therapies for treatment of TR may offer a safe and effective alternative to surgery in this high-risk population. OBJECTIVES: The purpose of this report was to study the 1-year outcomes with the TriClip transcatheter tricuspid valve repair system, including repair durability, clinical benefit and safety. METHODS: The TRILUMINATE trial (n = 85) is an international, prospective, single arm, multicenter study investigating safety and performance of the TriClip Tricuspid Valve Repair System in patients with moderate or greater TR. Echocardiographic assessment was performed by a core laboratory. RESULTS: At 1 year, TR was reduced to moderate or less in 71% of subjects compared with 8% at baseline (p < 0.0001). Patients experienced significant clinical improvements in New York Heart Association (NYHA) functional class I/II (31% to 83%, p < 0.0001), 6-minute walk test (272.3 ± 15.6 to 303.2 ± 15.6 meters, p = 0.0023) and Kansas City Cardiomyopathy Questionnaire (KCCQ) score (improvement of 20 ± 2.61 points, p < 0.0001). Significant reverse right ventricular remodeling was observed in terms of size and function. The overall major adverse event rate and all-cause mortality were both 7.1% at 1 year. CONCLUSION: Transcatheter tricuspid valve repair using the TriClip device was found to be safe and effective in patients with moderate or greater TR. The repair itself was durable at reducing TR at 1 year and was associated with a sustained and marked clinical benefit with low mortality after 1 year in a fragile population that was at high surgical risk. (TRILUMINATE Study With Abbott Transcatheter Clip Repair System in Patients With Moderate or Greater TR; NCT03227757).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Lurz P, Stephan von Bardeleben R, Weber M, et al. Transcatheter Edge-to-Edge Repair for Treatment of Tricuspid Regurgitation. J Am Coll Cardiol. 2021. PMID: 33478646. doi:10.1016/j.jacc.2020.11.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。